A trial led by a McMaster University respirology professor shows promising results for a new medicine for severe asthma patients.
The results of the trial, published this week in the New England Journal of Medicine, demonstrate that patients treated with a potential new medicine and antibody, called benralizumab, were more than four times likely to reduce their usage of oral corticosteroids than those taking a placebo.